Madrigal Pharmaceuticals, Inc. (MDGL)
| Market Cap | 11.76B +63.0% |
| Revenue (ttm) | 1.13B +256.8% |
| Net Income | -309.44M |
| EPS | -13.65 |
| Shares Out | 23.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 235,015 |
| Open | 494.06 |
| Previous Close | 497.03 |
| Day's Range | 490.13 - 511.11 |
| 52-Week Range | 265.00 - 615.00 |
| Beta | -1.04 |
| Analysts | Strong Buy |
| Price Target | 671.58 (+31.62%) |
| Earnings Date | May 6, 2026 |
About MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Financial Performance
In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price target is $671.58, which is an increase of 31.62% from the latest price.
News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associa...
Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
Canaccord lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $578 from $587 and keeps a Buy rating on the shares. The firm updated its model following Q1 results…
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Evercore ISI lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $649 from $652 and keeps an Outperform rating on the shares.
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
Reports Q1 revenue $311.34M, consensus $300.92M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “2026 is off to a terrific start. Rezdiffra has achieved blockbuster status on a trailing-12-...
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Clear Street raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $680 from $533 and keeps a Buy rating on the shares post the Q1 report. The firm says…
Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026
Rezdiffra posted $311M in Q1 2026 net sales, up 127% year-over-year, with over 42,250 active patients and strong market expansion. The company is investing in a broad pipeline and expects robust growth, though profitability is not anticipated in 2026.
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
Arrowhead Pharmaceuticals (ARWR) announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference therapeutic designe...
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead Pharmaceuticals Precision approach targets patients who have a mutation in the PNPLA3 gene,...
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for AR...
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2...
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
14:57 EDT Madrigal Pharmaceuticals (MDGL) off highs, remains up 13% in afternoon trading
Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Rezdiffra is driving strong revenue growth, with 2025 sales projected near $1 billion and a robust pipeline expansion. Market penetration remains low, offering significant upside, while international growth and new combination therapies are set to accelerate from 2027 onward.
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference ...
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $529 from $570 and keeps a Neutral rating on the shares. Following quarterly results and the associated call, the…
Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025
Rezdiffra achieved nearly $1B in first-year net sales, driving robust growth in a rapidly expanding US MASH market. The company expects continued strong performance in 2026, supported by a deep pipeline, broad payer access, and a strong cash position.
Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
Reports Q4 revenue $321.083M, consensus $312.74M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “2025 marked a defining year for Madrigal. We solidified our position as the undisputed lead...
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025 , more than 36,250 patients on Rezdiffra Built industry-lea...
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced t...
Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo
Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA prog...
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA
BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $570 from $595 and keeps a Neutral rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings…
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thurs...
Madrigal Pharmaceuticals initiated with an Overweight at Barclays
Barclays initiated coverage of Madrigal Pharmaceuticals (MDGL) with an Overweight rating and $964 price target Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positi...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...